Matinas BioPharma Hldgs Bolsa (AMEX: MTNB)

Últimas noticias sobre Matinas BioPharma Hldgs (AMEX:MTNB) Bolsa

Matinas BioPharma Hldgs

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Holdings Inc

News

Rumble Says Bitcoin Allocation Strategy Will Include Purchases, At Its  Discretion, Of Up To $20M

A major legal battle looms for Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) as the company prepares for an April trial, announced Monday, to face allegations from the U.S. Federal Trade Commission (FTC) over its acquisitions of <a href="https://www.benzinga.com/topic/meta">Instagram and WhatsApp.</a>
The FTC claims Meta strategically acquired the platforms in 2012 and 2014 to suppress competition in the social media space, accusations the company strongly denies, Reuters reports.
What Happened: The trial, set for April 14, comes after Judge James Boasberg rejected Meta's bid to dismiss the case. The FTC argues that Meta's actions have maintained its dominance in the social networking market at the expense of innovation and consumer choice. 
The lawsuit suggests that without the acquisitions, Instagram and WhatsApp could have evolved into independent competitors capable of challenging Meta's position.
Also Read: <a href="https://www.benzinga.com/24/11/42176317/exclusive-small-caps-hit-records-yet-russell-2000-is-still-very-discounted-relative-to-the-sp-500-expert-says">EXCLUSIVE: Small Caps Hit Records As Expert Says Russell 2000 &#8216;Still Very Discounted&#8217; Compared To S&amp;P 500</a>
The FTC filed its lawsuit in 2020, alleging that Meta violated antitrust laws by eliminating competition through its high-profile acquisitions. While Meta contends its investments have enhanced user experiences, the agency has expressed concerns over market consolidation and potential abuse of monopoly power. 
Judge Boasberg acknowledged the difficulties of applying traditional antitrust frameworks to evolving digital markets, stating, "The Commission faces hard questions about whether its claims can hold up in the crucible of trial." The judge also noted Meta's arguments regarding competition from platforms like TikTok and YouTube warrant examination during the proceedings.
Why It Matters: If the FTC succeeds in proving its case, it could set a precedent for tech industry antitrust enforcement, potentially reshaping the digital landscape. Meta's spokesperson argues that the acquisitions, which brought Instagram and WhatsApp under its umbrella, have significantly benefited users through improved services and accessibility.
The case builds on past regulatory concerns. The FTC recently alleged <a href="https://www.benzinga.com/news/24/06/39189663/mark-zuckerbergs-meta-withheld-key-details-in-instagram-and-whatsapp-acquisitions-ftc-claims">Meta withheld critical information</a> during its acquisition reviews, a claim supported by newly surfaced evidence. This follows earlier fines in Europe for similar issues surrounding the WhatsApp deal.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/retail-sales/24/11/42170721/thanksgiving-dinner-gobbles-up-19-more-cash-this-year-many-holiday-hosts-already-regret-their-decision">Thanksgiving Dinner Gobbles Up 19% More Cash This Year, Many Holiday Hosts &#8216;Already Regret Their Decision&#8217;</a></li>
</ul>
Photo: Shutterstock

Government

Social Media

Legal

Tech

Meta Heads To Trial Over Instagram, WhatsApp Acquisitions

After factoring in estimated closing adjustments and new non-recourse project-level debt, the Company expects its total long-term corporate capital commitment to acquire the project to be approximately $70-75 million, which the Company expects to fund with existing sources of liquidity.
The Company expects the transaction to close in the first quarter of 2025, after which its targeted contribution to fiscal year 2025 results will be communicated.

CWEN

Clearway Energy Enters Binding Agreement To Acquire Operational Tuolumne Wind Project From Turlock Irrigation District

Earnings

Guidance

SUPV

Grupo Supervielle Q3 Net Income AR$8.9B; Confirm 15% ROE Guidance For FY2024

The jury found that Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal – Guardant Health's tissue-free minimal residual disease (MRD) test for early-stage colorectal cancer (CRC) – in favor of Signatera&#x2122;, Natera's competing product.&nbsp;

NTRA

Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages

CHCI

Comstock Holding Says Carr Workplaces Signed New 26,331 Square Foot Lease At The Hartford In Arlington, Virginia

Shares of Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) traded higher on Monday in response to President-elect Donald Trump&#8217;s plans to nominate Marty Makary to lead the Food and Drug Administration (FDA). Here&#8217;s <a href="https://www.benzinga.com/quote/HIMS/news">what you need to know.</a>
What To Know: Market optimism surrounding Makary's selection may have bolstered Hims &amp; Hers shares on Monday as investors anticipate that the nomination could bring favorable regulatory changes to the sector. Makary is a proponent of telehealth and an executive at Sesame, a company that connects consumers to physicians who can prescribe compounded weight-loss drugs.
Hunterbrook Capital released a <a href="https://hntrbrk.com/hims-follow-up/">bullish report</a> on Monday announcing a long position in Hims &amp; Hers Health, citing potential benefits from Makary&#8217;s leadership at the FDA. The report suggests that Makary's background and expertise could stabilize the compounded GLP-1 drug market, in which Hims &amp; Hers Health is actively involved.
The report also highlighted regulatory challenges Hims &amp; Hers Health has faced, including fluctuating FDA guidance on <a href="https://www.benzinga.com/news/earnings/24/11/41718402/whats-going-on-with-hims-hers-health-stock-monday">drug shortages</a> and scrutiny over its prescribing practices. Makary's history with telehealth and compounded drugs may signal a more supportive regulatory environment, driving investor optimism.
Hims has been expanding into the weight-loss drug market with compounded GLP-1 products, which are cheaper alternatives to branded drugs like Wegovy and Mounjaro. Regulatory clarity under Makary's potential leadership is seen as a positive development for the company.
HIMS Price Action: Hims &amp; Hers shares closed Monday up 23.9% at $31.39, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-1024x532.png" alt="" class="wp-image-664105" style="width:530px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1.png 1468w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/24/11/42172722/gold-down-over-3-rigetti-computing-shares-spike-higher">Gold Down Over 3%; Rigetti Computing Shares Spike Higher</a></li>
</ul>
Image: Mohamed Hassan from Pixabay

Movers

Hims & Hers Health, Inc. Class A Common Stock

HIMS

What's Going On With Hims & Hers Health Stock Monday?

HSAI

Hesai Group Expects Q4 Net Revenues To Approach $100M

Agora Expects Q4 Total Revenues To Be $34M - $36M, Also Expects Significant Improvement In Net Income / (Loss)

Hesai Q3 Adj EPS $(0.05) Misses $(0.02) Estimate, Sales $76.87M Beat $69.82M Estimate

For NBC, big balloons mean a bigger budget.
What Happened: The Macy's Thanksgiving Day Parade, known for its extravagant performances and cartoon character floats, is getting pricier. 
Since 1953, the peacock-branded network has aired the iconic turkey-day tradition. And, according to <a href="https://www.wsj.com/business/media/nbc-ready-to-pay-triple-to-gobble-up-thanksgiving-parade-broadcast-rights-e18fd95f?mod=hp_lead_pos5">The Wall Street Journal</a>, NBC is considering a $60-million agreement — triple the current $20 million rate — to secure those rights through the next decade. 
See Also: <a href="https://www.benzinga.com/news/retail-sales/24/11/42170721/thanksgiving-dinner-gobbles-up-19-more-cash-this-year-many-holiday-hosts-already-regret-their-decision">Thanksgiving Dinner Gobbles Up 19% More Cash This Year, Many Holiday Hosts &#8216;Already Regret Their Decision&#8217;</a>
So why the hefty price? Consider the appeal of live events in a streaming-dominated world. 
Comcast Corp.-owned (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) NBC and other traditional forms of TV are struggling to keep audiences after the whole cord-cutting trend. Marquee moments like parades, football games, boxing matches and awards shows are now popping up streaming services.
For NBC, the bet is that Peacock streaming customers will tune into the Nov. 28 crowd-pleaser, which is expected to feature celebrity appearances and live Broadway performances. 
Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) can relate. The Burbank, California-based conglomerate shelled out a 20% premium to swipe the Grammy Awards from Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>), which had been airing it on CBS.
Why It Matters: The value of a live audience is as buoyant as a giant Snoopy balloon.
Nearly 30 million viewers tuned in to watch last year's parade, and this Thursday morning promises another spectacle of at least 11 marching bands, 28 clown crews, 22 balloons and 33 floats.
As for performers, viewers can expect a lineup of famous faces, including Charli D'Amelio, original &#8220;Wicked&#8221; star Idina Menzel, &#8220;Tonight Show&#8221; host Jimmy Fallon with The Roots, Coco Jones, Liza Colón-Zayas, The Temptations, T-Pain and the New York Liberty.
The route stretches 2.5 miles. It begins at 77th Street and Central Park West and winds its way down to Macy's Herald Square, the flagship store of Macy&#8217;s Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>).
For those in New York City eager to preview the parade prep, the balloon inflation event happens Wednesday, Nov. 27, on the Upper West Side — a chance to get up close and personal with the towering inflatable icons.
Per <a href="https://www.usatoday.com/story/entertainment/tv/2024/11/21/macys-thanksgiving-day-parade-2024/76454992007/">USA Today</a>, this year&#8217;s event will debut new balloons, including Minnie Mouse, the Extraordinary Noorah and Gabby from Gabby&#8217;s Dollhouse.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42162655/macy-falls-as-preliminary-q3-highlights-mixed-performance-and-154-million-expense-concealment">Macy&#8217;s Delays Q3 Earnings Report Amid Investigation Over $154M Accounting Scandal; Stock Dips</a></li>
</ul>
Photo: Shutterstock

Entertainment

Events

Media

CMCSA

PARA

PARAA

Peacock Pays Up: Macy's Thanksgiving Parade Costs Set To Balloon For Content-Hungry NBC

Faraday Future plans to announce the date and detailed plan for the stock ticker symbol change in January 2025.
 &nbsp;

FFIE

Faraday Future Plans To Change its Stock Ticker Symbol From 'FFIE' To 'FFAI' In Early 2025

Agora Q3 EPADS $(0.26) Down From $(0.23) YoY, Sales $31.6M Down From $35.0M YoY

Offerings

State Street Plans Issuance Of $2.25B Of Senior Debt By Its Principal Banking Subsidiary, State Street Bank And Trust Company

IPOs

CGTL

Creative Global Technology Plans Pricing Of Its IPO Of 1.25M Ordinary Shares At $4.00 Per Share For Total Gross Proceeds Of $5M; To Commence Trading On November 26, Under The Ticker Symbol 'CGTL'

Eastman Kodak Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) shares closed Monday&#8217;s session up more than 18% after the company announced plans to terminate its U.S. pension program. Here&#8217;s <a href="https://www.benzinga.com/quote/KODK/news">what you need to know.</a>
What To Know: In a new regulatory filing, Kodak said the Kodak Retirement Income Plan Trust entered into a purchase and sale agreement with Mastercard Foundation in which Mastercard will purchase certain private equity ownership interests and other illiquid assets. 
Kodak will sell the illiquid assets with a value of $764.4 million for a purchase price of $550.6 million in cash. Additional buyers will acquire $87.3 million in assets.
According to <a href="https://www.wsj.com/articles/kodak-prepares-to-terminate-u-s-pension-book-gain-of-more-than-500-million-d0cfb621?mod=lead_feature_below_a_pos3">The Wall Street Journal</a>, Kodak&#8217;s pension plan is overfunded, with $3.5 billion in assets and $2.3 billion in liabilities. The termination process will involve selling illiquid assets, settling liabilities and replacing the plan with a new retirement program. 
The termination is expected to result in a cash gain of $530 million to $585 million after taxes. Kodak plans to use these proceeds to reduce its $460 million in long-term debt, which includes a 12.5% term loan. Under its credit agreement, the company must reduce its debt balance to $200 million with proceeds of this size.
This move is aimed at improving Kodak's financial health, reducing interest expenses and investing in core business areas like pharmaceutical chemicals. The process is expected to take over a year and plan participants will retain the full value of their benefits through annuities or lump-sum payouts.
Kodak closed its latest quarter with $214 million in cash after reporting a quarterly profit of $18 million.
KODK Price Action: Eastman Kodak shares closed Monday at $6.24 after gaining 18.4% during regular trading hours, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="542" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-1024x542.png" alt="" class="wp-image-664229" style="width:483px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK.png 1464w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/11/42174446/streaming-vinyl-propel-music-copyright-value-to-45-5-billion">Streaming, Vinyl Propel Music Copyright Value To $45.5 Billion</a></li>
</ul>
Photo: <a href="https://pixabay.com/users/jbooba-23039065/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=7452562">Gregor Mima</a> from Pixabay.

KODK

Kodak Stock Is Trading At 52-Week Highs: What's Going On?

Tim Draper, a prominent venture capitalist and cryptocurrency enthusiast, has made Bitcoin price predictions since 2014.
That year, Draper predicted Bitcoin to be $10,000 by the end of 2017. Despite skepticism, his forecast proved accurate, as Bitcoin hit $10,000 in November 2017 during its dramatic bull run.
In 2018, Draper forecast Bitcoin to reach $250,000 by the end of 2022. This bold prediction was not fully realized, though Bitcoin did reach an all-time high of approximately $69,000 in November 2021.
When Bitcoin failed to hit the target price in 2018, Draper extended the timeline to mid-2023. The futurist and investor based this target price on mass adoption, particularly by women and retail investors.
Draper said in an interview with Benzinga: "My first prediction was in 2014 when Bitcoin was at $180. I said that it would be $10,000 in three years. Sure enough, by the end of 2017, Bitcoin hit $10,000. Since then, I have not been as prescient. I thought Bitcoin would hit $250,000 by 2022! I think I am going to be three years off.&#8221; Draper added: &#8220;I think we can chalk those three years up to a weak government that regulated rather than encouraged new technologies. Our new government is more encouraging."
Since the U.S. presidential election in November, the crypto world has been celebrating with a decidedly more bullish outlook. Though many tokens have seen significant gains, including Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), Bitcoin has taken center stage, reaching a record high of $99,000 on Nov. 21, the second all-time high of the month.
Benzinga asked Draper what his prediction was for Bitcoin with the end of 2024 rapidly approaching and he responded: "This is just the beginning! If you are asking about price prediction, I would say about Bitcoin will reach about $120,000 by end of year."
Benzinga asked Draper what drives his future forecasts for Bitcoin, he pointed to the superiority of the cryptocurrency over traditional fiat and long-term trends in usage.
"It is a long-term trend. Bitcoin is just better technology than using banks and governments as the trusted third party. It is transparent, global, open, keeps perfect records, etcetera. It will make the world wealthier. When retailers (for currency) and governments (for taxes) realize that Bitcoin will save them money on each transaction, then there will be a great incentive for everyone to use Bitcoin."
When asked for his prognostication for 2025, Draper said he is holding out for the $250,000 level and cited the proposed U.S. Bitcoin reserve as a contributing factor.
"Assuming a standard supply and demand curve, if there is a big buyer like that, the price will continue to rise. I think 2025 is the year Bitcoin will finally hit my mark of $250,000," Draper noted.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42165734/bitcoin-etfs-registered-record-312-billion-net-inflows-last-week">Bitcoin ETFs Registered Record $3.12 Billion Net Inflows Last Week</a>
<h1 class="wp-block-heading">MicroStrategy Leads the Bitcoin Charge</h1>
Michael Saylor, co-founder of MicroStrategy, <a href="https://x.com/saylor/status/1861033309934862601">tweeted today</a><a href="https://x.com/saylor/status/1861033309934862601" target="_blank" rel="noopener"> </a>that the company acquired $5.4 billion in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), the single biggest purchase of the world's leading decentralized digital currency.
In the tweet, Saylor stated, "MicroStrategy has acquired 55,500 BTC for ~$5.4 billion at ~$97,862 per #bitcoin and has achieved BTC Yield of 35.2% QTD and 59.3% YTD. As of 11/24/2024, we hodl 386,700 $BTC acquired for ~$21.9 billion at ~$56,761 per bitcoin. $MSTR"
This is after the news that the company is making $500 million a day with its Bitcoin holdings, which Saylor said have appreciated by $5.4 billion over the past two weeks. Saylor predicted Bitcoin could reach $13 million by 2045, which would elevate its market cap to $250 trillion. 
<h1 class="wp-block-heading">Optimism Among Web3 Leaders</h1>
Nathan Berkley, CEO of Muhdo Health Limited, a health technology company specializing in DNA and epigenetic testing which incorporates cryptocurrency into its operations, has a bullish outlook on Bitcoin and independently concurs with Draper's forecast.
"I think we could see Bitcoin hit $120,000. With U.S. sentiment being positive to this market now, and understanding Web3 can have real impact, it's a great time to be in the space," Berkley noted.
Lisa Loud, executive director of Secret Network Foundation, a blockchain platform designed to enable privacy-preserving decentralized applications, said: "The Bitcoin of today is not the Bitcoin of 2020: we have a broader finance interest, politics, and uncertain regulatory changes. A conservative estimate would say it will end in the range of $92,000-115,000, but if we get a large opt-in from mainstream, we could blow this estimate out of the water."
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42173367/shiba-inu-burn-rate-soars-487-in-a-day-what-is-going-on"> • Shiba Inu Burn Rate Soars 487% In A Day: What Is Going On?</a>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

Trading Ideas

$BTC

$ETH

$SOL

$USDT

$XRP

EXCLUSIVE: Tim Draper Predicts Bitcoin To Reach $120K By End Of 2024, $250K In 2025

The Q4 earnings report for Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) was released on Monday, November 25, 2024 at 04:00 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
During the previous quarter, the company beat on EPS by $0.4, leading to a 0.0% increase share price change the next day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLBD

Earnings Summary: Blue Bird Q4

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.
Revenue was down $4.33 million from the same period last year.
<h3>Earnings History Overview</h3>
Last quarter the company beat on EPS by $0.38 which was followed by a 1.0% increase in the share price the next day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTA

Enanta Pharma Earnings Analysis: Q4 Recap

The Q4 earnings report for Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) was released on Monday, November 25, 2024 at 04:02 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 10.0%, reporting an EPS of $-0.18 versus an estimate of $-0.2.
Revenue was down $80.66 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.11 in the last quarter, resulting in a 6.0% increase share price change the following day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.21</td>
<td>0.80</td>
<td>-0.14</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>0.99</td>
<td>0.01</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>887.42M</td>
<td>619.95M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CENT

Central Garden & Pet: Q4 Earnings Insights

Matinas BioPharma Holdings, Inc. 2024 Q2 - Results - Earnings Call Presentation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Matinas BioPharma Hldgs (NYSEMKT:<a href="https://investorplace.com/stock-quotes/mtnb-stock-quote/">MTNB</a>) just reported results for the second quarter of 2024.<ul><li>Matinas BioPharma Hldgs reported earnings per share of -2 cents. This met the analyst estimate for EPS of -2 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mtnb-stock-earnings-matinas-biopharma-hldgs-for-q2-of-2024/">MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024

Matinas BioPharma (MTNB) has provided an update. The Company has updated its corporate presentation for use at upcoming conferences and investor me...

Matinas BioPharma Releases Updated Corporate Presentation

Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price...

Buy Rating Affirmed: Matinas BioPharma's Solid Financials and Promising Drug Development

These are the upcoming stock splits for the week of September 2 to September 6, based on&nbsp;TipRanks' Stock Splits Calendar. A stock split is a c...

Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested

Maxim downgraded Matinas BioPharma (MTNB) to Hold from Buy. The company announced that partnering negotiations for its lead asset MAT2203 – oral am...

Matinas BioPharma cut to Hold at Maxim on termination of MAT2203 talks

Matinas BioPharma plunges as deal for lead asset falls apart

Alliance Global Partners downgraded Matinas BioPharma (MTNB) to Neutral from Buy without a price target after the company announced that negotiatio...

Matinas BioPharma downgraded to Neutral from Buy at Alliance Global Partners

Matinas BioPharma Holdings (MTNB) has disclosed a new risk, in the Innovation / R&D category. Matinas BioPharma Holdings faces significant business...

Matinas BioPharma Faces Uncertain Future After Halting MAT2203 Development

DPRO

MTNB

WRIV

Press Releases

In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

General

Matinas BioPharma's LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Health Care

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Comments

Matinas BioPharma Hldgs

Noticias

Últimas noticias sobre Matinas BioPharma Hldgs (AMEX:MTNB) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL